D-0120
- Generic Name
- D-0120
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05665699
- Locations
- 🇺🇸
Study Center, Morgantown, West Virginia, United States
🇺🇸Site Center, Bellevue, Washington, United States
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 121
- Registration Number
- NCT05504083
- Locations
- 🇨🇳
Inner Mongolia Baogang Hospital, Baotou, China
🇨🇳Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT04097405
- Locations
- 🇺🇸
Syneos Health, Miami, Florida, United States
D-0120 Safety and PK/PD Study in China
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT03923868
- Locations
- 🇨🇳
Site 04, Bengbu, Anhui, China
🇨🇳Site 03, Nanjing, Jiangsu, China
🇨🇳Site 07, Nanjing, Jiangsu, China
D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT03291782
- Locations
- 🇺🇸
Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath